Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q3 FY23 results · Oct–Dec 2022
Cohance Lifesciences reported revenue from operations of ₹353.77 crore (down 9.7% from Q3 FY22) and net profit of ₹107.72 crore (down 32.7% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 353.77 | 391.59 | −9.7% | 278.40 | +27.1% |
| Other income | 13.01 | 64.69 | −79.9% | 10.92 | +19.2% |
| Total income | 366.78 | 456.27 | −19.6% | 289.32 | +26.8% |
| Profit before tax | 146.08 | 239.46 | −39.0% | 98.48 | +48.3% |
| Net profit for the period | 107.72 | 160.07 | −32.7% | 72.06 | +49.5% |
| EPS, basic (₹) | 4.23 | 6.29 | −32.8% | 2.83 | +49.5% |
| Net margin (%) | 30.4 | 40.9 | 25.9 |
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 348.49 | 391.59 | −11.0% | 278.40 | +25.2% |
| Other income | 12.51 | 9.27 | +34.9% | 10.39 | +20.4% |
| Total income | 361.00 | 400.86 | −9.9% | 288.79 | +25.0% |
| Profit before tax | 147.28 | 184.05 | −20.0% | 105.99 | +39.0% |
| Net profit for the period | 109.47 | 137.00 | −20.1% | 78.92 | +38.7% |
| EPS, basic (₹) | 4.30 | 5.38 | −20.1% | 3.10 | +38.7% |
| Net margin (%) | 31.4 | 35.0 | 28.3 |
Consolidated
- Filed with BSE
- 07 Feb 2023, 13:52 IST
- Board meeting
- 06 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Feb 2023, 13:52 IST
- Board meeting
- 06 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE